SCD
LMP Capital And Income Closed Fund
Mentions (24Hr)
0.00% Today
Reddit Posts
$ICU - SeaStar Medical Names David Green as Finance Chief, Mentions Commercial Launch of SCD-PED LATER THIS QUARTER (IMPLYING FDA APPROVAL)
$ICU - SeaStar Medical Issued U.S. Patent with Broad Claims Covering Use of the Selective Cytopheretic Device for Multiple Clinical Indications
CRSP Stock Surges after winning the first ever gene editing approval
ICU - SeaStar Medical, shirt squeeze incoming
SeaStar Medical Holdings (ICU) insane potential.
SeaStar Medical Holdings (ICU) insane potential.
$ICU 2.6 mill FLOAT deSPAC IMO we get back to $4's
$icu 2.6 mill FLOAT deSPAC IMO we get back to $4's
Medical Cannibas - $BGXX, My Why Buy
Amesite: Ed-Tech for Enterprises is a great SaaS play
SobrSafe Inc. - Addressing the $200B per year problem in the workplace
Champion Gaming: The Sports Betting Pick and Shovel Play
Troika Media: Swing trade of the year!
Global Blood Therapeutics (GBT) potential upside of ~172% over the coming months
$QIPT: Lots of ways to win - Part II The Catalysts
Mentions
Also SCD, major pull back again so the opportunity is still there. Government support as well.
CCCM (c3 metals) BYN (Banyan) SCD (Scandium) Been in cccm and byn for 3+ years. Scandium for like 5 months
SCD.V-Scandium Canada. The only Scandium deposit in North America. Canadian Gov. has listed it as a critical metal. Gave SCD almost $7M in grants to get mine operational. Guy Bourassa, CEO, is also MAKING other uses for Scandium to insure demand is there for the supply.
I’m in heavy for SCD. Next gen of light weight, strong, wear resistant metal of scandium-aluminum alloys. It will be a wait but it will be up. Federal investment and working with indigenous populations who are also invested. Might be years away though.
I'm in Wealthsimple, I have friends that use questrade. Personally I am into HGRAF, SCD, a nvidia etf which pays monthly dividends too. There are many many options out there, take a look around, and sometimes go with your gut after researching. If there is something your passionate about, look into that as well.
IMO a few cents won’t matter much when SCD hits a $1 or more. Check out the only other public scandium company Sunrise. Out of Australia, they had good feasibility results and a partnership and it sent their stock from .17 to $7. Not saying SCD will do the same but $1-2 on positive feasibility and road news is quite possible. GL
RZLV is an AI agent company in the UK that has an average price target of $11 (currently trading under $3) it’s held down because the company does semi annual earnings which sucks because they have to prove earnings but it should be a blowout. End of March or early April, the ceo has a bit of shady past so do your own due diligence on it but I think they are legit and will be a major player someday in the AI agentic sector. SCD is a scandium junior miner out of Quebec. Incredibly speculative but the Canadian government just gave them a major grant and put scandium on the critical mineral list. If you compare them to the only other public scandium miner which is in Australia they trade at 5.50 and hit $7 not long ago due to catalysts that are coming in the next few months for SCD aswell. SCD trades under .20 cad. Again major gamble but the upside is huge if it works out. Thats just the summary for each do your own research. Rezolve also has partnerships with Microsoft and Google which are the reasons for it hitting $7 a year ago
“Shaqballs” is kind of memorable 😂. I got in early on SLS, early and holding SCD as well. In a time where so many investors are panicking, I’ve had the best returns of my life and have to credit Reddit and real posters like you. Lots to weed through but it has been so helpful. Not familiar with RZLV. I’ll check it out. Thanks for sharing!
Yep. Thanks for remembering. I was beating the drums on both for months while people talked shit calling them scams 🤣 if I was petty I’d have alot of receipts but I’m just happy with my returns. Next is RZLV and SCD fyi. Not to the same level as SLS and HGRAF because they are both life changing but SCD will go to dollar land this year or next and RZLV is at least a 5xer. Not pump and dumps but legit companies. GL
SCD recent government announcement of 6.9million investment Potential news release of a joint road being built in Northern Quebec giving easier access in and out of the mine site
Scandium Canada. SCD.v Have a look at my post history and do your own due diligence. As always, only invest in mining what you're willing to lose, however a long term play like this may be what you're after.
Canadian stocks MAXQ SCD QIMC HG HHE SCY
HGRAF and SLS will both have generational returns over the next 5+ years IMO. SLS will be bought out this year for a major premium after they release phase 3 data. HGRAF is going to change the materials game in many different ways. Graphene is the future. SCD is a fun little penny stock out of northern Quebec. It’s pumped a lot so far so I’d wait for a dip but I loaded up in the early .10s. It’s one of the largest scandium mines in the world and if the Canadian government backs them financially the stock will be significantly higher than it is now. Scandium is classified as a rare metal now and will be scarce in the future and needed. Worth a look. The SCD sub is better as you can find smarter peoples dd posts lol
HGRAF is right up my alley, but still a little too speculative for me and I’m trying to learn more. SLS is a pass for me just because it’s biotech. What SCD? I really like my high conviction plays In in, but never hurts to look for new ones!
Smart fella! Not often you see those on this sub hahaha. You got an eye on SCD and HGRAF? Those are my two pennies besides SLS that I’m banking on long term. SLS won’t be a penny stock for long tho.
I bought HYMC a month ago and SCD. So far so good. Hold for gold.
Nothing because I already dumped all my disposable income in to SCD
Appreciate all the downvotes lol either way, I'll reply cordially (as a typical Canadian does lol) Our space/defense and everything linked to it is booming, and will over the coming years. Canada has committed massive money to support rare earth minerals, aerospace and defense (which has been long overdue). Kraken robotics is one of the major companies growing exponentially right now. They own the patents on the seapower batteries (the current best batteries for underwater UUV's) which are used in Anduril subs. Anduril just signed a 1.1 billion dollar deal to deliver a fleet of ghost shark subs to Australia, and every GS has ~9 Million in Kraken tech. Kraken also owns patents on underwater lidar/sonar and lead the world in underwater imaging technology. They just built a new manufacturing facility about to come online that will increase production by 300%. They will only keep growing. Volatus is a drone company that is making noise. They have increased profits YoY and provide service as well as equipment. Their fleet consists of over 90 different types of drones for all areas (defense, fiest response, border patrol, deliveries, etc). They also are about to increase production with a 200,000 square foot facility, only an upward trend. Canada is investing in space sovereignty. Currently building multiple space ports and investing heavily into R&D for rocket technology. A few notable companies that are growing include MAXQ and MDA space. MDA is the bigger company, they develop robotics for space (including Canadarm3) and have been in the business for 40+ years. They have a massive backlog of orders that is currently larger than their market cap. Then on the supply side there is heavy investment into mining. Canada has tons of rare earth minerals and the government is handing out grants to spur growth. Recently rio tinto received 25 million to increase Scandium production, for example. There are sleeper companies like SCD who are set to become a major supplier of Scandium to the world. SCD owns the second largest Scandium deposit in the world, and the largest in the north America. They also own an R&D division that already has 2 scandium-aluminum alloys that can be 3d printed (HUGE for aerospace and advanced manufacturing). To give some context, Lockheed Martin signed an MOU with sunrise earth metals to buy 15 tons of Scandium per year, and the Pentagon gave 10 million to Lockheed who hired Niocorp to develop aluminum Scandium alloys for aerospace. SCD already has 2, and are developing more. These are just a few to name. Canada is finally investing where it should to grow the economy and take advantage of our resources, and increase defense spending. Currently, we are less than 2% GDP on defense, but are increasing it with a goal to hit 5% by 2035. These are all pieces of the same pie that is currently booming, but many aren't even aware of it yet.
SCD, disclaimer I do not know how to analyze stocks from a financial analysis perspective or to validate the fair value of a stock or to evaluate if a company is capable of operating, BUT scandium alloys are extremely exciting SCD focuses a lot on AlSc for 3d printing etc but what really excites me is extruded 7000 series SC alloys. There is a paper from the early 2000s by a saudi guy that just goes over it and it’s amazing. up to 650MPa yield strenght ( will probably be more nowadays) great fatigue characteristics higher operating temps, etc. all of this at the density of aluminum, meaning it’s both very high specific strenght (higher than titanium alloys) while being much easier to form (machining AND casting AND have good weld ability) than composite while also being less of a pain to design with than composite (Al is isotropic) and also having a better tolerance to damage. did i mention it can also replace steel in outdoor application since it’s corrosion resistant, had the required strenght and ends up being cheaper (assuming production matures) per MPa of yield strenght ? it’s a cool thing for me cause i want to be able to spec it on my designs at work, but is the company well managed etc ? I have no idea do your own research. I own a bit of SCD (it’s small since i just started but it’s a big chunk of my portfolio (it’s about 120CAD)) so i am biased
Random example from Canadian venture exchange: https://ca.finance.yahoo.com/quote/SCD.V/ You might think they are the exception. You would be wrong. By, Nasdaq
Scandium Canada is sitting on one of the world's biggest scandium deposits (Crater Lake, QC). They've applied for major funding from Canada's Critical Minerals Infrastructure Fund (CMIF) — a $1.5 B federal program backing strategic metals. That decision is due this fall. If approved, it's a non-dilutive, government-validated boost that could completely re-rate the stock. Scandium is critical for aluminum alloys used in EVs, aerospace, and defense - and right now, supply is basically China + Russia. Canada wants a domestic source. If Ottawa signs the check, SCD.V goes from microcap to national asset overnight.
Comfortable to hold Scandium Canada (SCD) (OTC : SCDCF) long term Second world biggest primary Scandium Deposit and 1st in North America
Thanks for the $20 SCD lunch got paid for!
Actually not a fortune but if I see something interesting I look further into it and if it checks out I do buy a small position. Worked out well for SCD and some others average return about 40% but you have to weed out the pumps on some and some obviously they didn't pass my sniff test.
Depends on what you're looking for, micro, small, mid or large cap. Micro I'm bullish medium and long term on SCD and have said so a lot Large cap, you can't go wrong with RY Enbridge CN rail. Mid cap....PRI AGF Sunlife. I don't hold any small cap so I can't offer value here. Whatever you're looking for, research someone's suggestion first.
I'll stick with my regular comment of SCD. Real potential but real risk, read up on here but make sure to do your own DD should you decide to jump in.
I like where it’s going in mining with Carney’s announcements. I’ve also put a bit into Scandium Canada SCD - reportedly the only actual Canadian mine with scandium deposits (as opposed to off shoots of other mines) and seen some modest gains.Also a bit into the Sisson Project in NB - North Cliff Resources. Volatile but one of the seven Carney announced projects). Also volatile, but West High Yield Resources for their magnesium mine in BC (WHY). That’s still waiting on approvals but I think the current political climate is pushing things through so taking the risk that it will go higher.
UAMY NB HOOD SCD.V maybe oklo
Looks like the government may help with this. SCD looking at a potential 25m in government grants and financing
I was pleasantly surprised to see institutional holders if SCD was up to just over 7% so that's pretty cool
this is yesterdays news. SCD is waiting on a government announcement for a 25m investment. its mentioned in this article (not the amount but the investment).
Anyone in on SCD.V? Currently up 25% at $0.13 PS.
Shockingly accurate especially based on predicted yields so far for scandium and other rare earth metals. SCD even with current outstanding shares could see a market value over 1b IF it ends up a fully operational mining company, not to mention the added value of patents. This translates to a fair market value of about 2.77 cad.
SCD.V SCDCF My best long term play atm. Can’t wait til it pops
I actually agree with you on SCD.V. Bought some last week and it was up 21% yesterday. With all the rare earth increases I like this one for future gains.
SCD.V SCDCF super under the radar play for the next while
Kk sounds good, please respond when you have had a chance to look. I didn't notice any gold with SCD. I did see the refinement patents and over 100 square km of land they have in QC. But clearly I missed gold mining. Will have to take another look today
Have you looked into the potential of SCD on the tsx? Scandium Canada. Patents and land, looks way undervalued with a huge potential upside, but I'd appreciate another perspective
SCD.V minerals play looking like a good setup
So interesting, I personally know a few people with SCD so I’ll be looking into this one further for sure. There’s not much out there by way of curative treatments for SCD.
Hoping SCD.V is the next metals play
I held SCD before so i was thinking of that. Gonna chk out the other though and see what im poss missing there. Thanks!
A couple of higher yielding managed ETFs I like are SCD and JRI. Maybe worth a look for you.
That’s a fair take and agree that the PED program does provide a floor, but I still view SeaStar as mostly binary: * **HDE limits PED adoption.** Each hospital needs separate IRB approval, which takes months. Even 1.5 years post-approval, adoption is still limited. Without strong adult data, full FDA approval for QUELIMMUNE is far from certain. * **Adult trial failure could hurt credibility.** A weak NEUTRALIZE-AKI outcome may raise doubts about the SCD platform overall, slowing FDA progress and payer confidence for both adult and pediatric use. * **Acquisition risk.** If the tech truly disrupts, big pharma could step in , but possibly to shelve it, not grow it, especially if it threatens existing revenue. * **Dilution risk remains.** Even with some PED growth, more funding is likely needed before adult revenues. One offering at current prices could dilute shareholders another 10 to 20%. So while the downside isn’t zero, I still think the real upside. Institutional interest will make the difference, depends on the adult trial. I'm confident it will not failt, but it will still be the most important event for Seastar so far.
I hear you. Cash via revenue would be great ANY DAY now. Been following this stocks since the pediatric SCD FDA approval. Just feeling like they sort of “owe” us an update on when the company is going to make revenue. It’s not a big ask.
ARA has nearly grown 100% for me. SCD and SCY are looking well. FL and [MILI.CN](http://MILI.CN) also up. If I wasn't already at my target allocation for critical minerals...
I am interested in their LNP heme editing approach for SCD/Beta-Thal. Its the clear winner for the disease space because it does not require the harmful conditioning regime that Casgevy does. On the other hand they are down to $200M in cash and many other companies are pursuing the same approach. I think it keeps squeezing with the rest of the biotech sector.
I've mostly bet on small cap and often pre-profit companies hoping for eventual high returns. Especially bullish on Scandium Canada (SCD.TO), and I'm up a high double digit on Aclara Resources (ARA.TO). Also in MILI Military Metals and FV Frontier Lithium.
$ICU (SeaStar Medical), through the AREVA Institute, announced a $2M DoD grant to advance their breakthrough research on severe burn treatment. [AREVA Institute and SeaStar Medical Announce DoD Award of Prestigious Military Grant to AREVA Institute to Evaluate SeaStar Medical’s SCD Therapy to Advance Breakthrough Burn and Sepsis Research](https://www.globenewswire.com/news-release/2025/06/11/3097525/0/en/AREVA-Institute-and-SeaStar-Medical-Announce-DoD-Award-of-Prestigious-Military-Grant-to-AREVA-Institute-to-Evaluate-SeaStar-Medical-s-SCD-Therapy-to-Advance-Breakthrough-Burn-and-S.html)
This company has no idea what they are doing with aramchol. It’s been NASH, AIDS, gallstones, oncology. Just give up already. It looks like SCD1 isn’t a great target. Now they’re reformulating semaglutide for sublingual? Meanwhile, oral semaglutide literally exists. I don’t see the point. Also, they’re based out of Israel. I’m done investing in and working with companies out of Florida and Israel. Nothing but grifters. CEO’s total comp was 1.7M for 2024. That’s a pretty large amount for a company with a $3M market cap.
Underlying robotics, defence and a lot of the other advanced sectors - My bet is on Rare Earth minerals developed in the west, especially Canada (for me). Currently I'm invested in Scandium Canada (SCD.TO) which I'm VERY bullish about because of their progress in alloy creation and ongoing improvements. They are nearly exiting pre-viability into actual production, which would be big for me since I have a significant holding. I'm also in Frontier Lithium, Aclara mining for magnet production, and Military Metals (for antimony). Although these are all high risk except perhaps Frontier and Aclara who'd be Medium (at best), I'm hoping that large scale societal investments will come within the next 10 years as governments continue to realize that full dependence on China for these vital supply chains is unsustainable. Clear energy, electric vehicles, defence, drones, space... In the end, all of them rely on mineral production. So, that's why bet, and why.
To all NVDA put sellers, call buyers and shareholders >Sudden cardiac death (SCD), a leading cause of mortality worldwide, is estimated to affect 4-5 million people annually. It's responsible for more than half of all cardiac deaths and up to 20% of overall deaths. SCD can occur in people of all ages, even those who appear healthy. What if Jensen has a heart attack during this 3-day weekend? At what price you think the stock will open on Tuesday?
GLMD Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor
Per Grok 1. For BLRX, at $2.96, a surge to $26 (the H.C. Wainwright target) would require relatively little volume if the float is, say, 1.5 million ADSs. For example, 500,000 shares traded (a third of the float) could trigger a squeeze, pushing the price up fast. Retail investors chasing quick gains might find this appealing, especially after the March 31, 2025, press conference highlighted pipeline momentum and cost efficiencies. 2. Short Squeeze Opportunities: Low-float stocks are prime candidates for short squeezes if short interest builds. As of early 2025, BLRX’s short interest was around 5.61% of its float (per MarketBeat data), or roughly 84,000-112,000 ADSs if the float is 1.5-2 million. If positive news—like a new in-licensing deal or SCD trial data—sparks buying, short sellers covering could amplify the rally. Retail investors who got in early could see outsized returns, as seen in past low-float biotech runs (e.g., Cassava Sciences in 2021). 3. Amplified Impact of Catalysts: The press conference emphasized upcoming catalysts: in-licensing new assets in 2025, CheMo4METPANC interim results (2026-2027), and SCD trial progress. With a low float, these events could disproportionately move the stock. For instance, a $10 million milestone payment from Ayrmid (part of the $87 million potential) could double the current $11.45 million market cap, and limited shares mean the price reacts sharply. Retail investors might see this as a chance to ride speculative waves. 4. Retail-Driven Momentum: Low-float stocks often attract retail trader communities (e.g., on X or StockTwits), where coordinated buying can gain traction. BLRX’s small size and recent strategic pivot to "BioLineRx 2.0" could make it a buzzworthy pick, especially if X chatter picks up post-conference. This social momentum can draw in risk-tolerant investors seeking a "lottery ticket" play. ### Enticing Aspects and Caveats - Upside Potential: A move from $2.96 to $26 offers a 778% return, far exceeding typical market gains. The low float magnifies this possibility, making it a tantalizing bet for retail investors with small positions (e.g., $1,000 could become $8,780). - Volatility as Opportunity: The stock’s 52-week range ($0.14-$3.24) shows it can swing hard. Retail investors comfortable with day-trading or holding through dips might see this as a feature, not a bug. - Risks: The flip side is steep declines if catalysts disappoint. A low float cuts both ways—selling pressure can crash the price just as fast. Plus, BLRX’s ongoing losses (-$9.2 million in 2024) and reliance on milestones add fundamental risk. ### Conclusion BLRX’s low float is inferred from its post-split ADS count and typical biotech ownership patterns, likely landing it in the 1-2 million share range. For retail investors, the allure lies in potential rapid gains, short squeeze setups, and catalyst-driven spikes—benefits heightened by the float’s scarcity. It’s enticing for those who thrive on volatility and biotech speculation, but the high risk of wipeout demands caution. If the strategy shift and pipeline deliver, the low float could be a rocket booster; if not, it’s a rollercoaster with no brakes.
The reason for insane costs of simple things like screws is due to the government requirements. It’s not an off the shelf screw from Home Depot. Most parts are given a “Specification Control Document” (SCD) that has requirements for environmental testing, lot controls, etc. All the extra testing and traceability is what adds to the cost.
CRSPR Therapeutics SCD cure costs about $2m. There is a market for curing diseases, and a profitable one and they're just getting started.
Gene therapies are priced in millions of dollars, so even for rare genetic diseases such as HAE, AATD, SCD (diseases currently being targeted by gene editing companies) there is the potential to make billions in revenue. Also, the patient population will still grow as new humans are born with the disease since these therapeutic edits are somatic and not heritable. The first CRISPR based drug (Casgevy) was approved at the end of last year for sickle cell and is priced at $2.2M, and the manufacturer (Vertex) anticipates they can dose 35k patients across US and Europe.
A lot of people game the system [https://www.militarytimes.com/veterans/2023/09/25/va-officials-sound-alarm-on-uptick-in-veterans-benefits-scams/](https://www.militarytimes.com/veterans/2023/09/25/va-officials-sound-alarm-on-uptick-in-veterans-benefits-scams/) [https://www.va.gov/vetdata/docs/QuickFacts/SCD\_trends\_FINAL\_2018.PDF](https://www.va.gov/vetdata/docs/QuickFacts/SCD_trends_FINAL_2018.PDF)
Crsp - first to market treating SCD, 2B in cash for runway, opening up in markets all over the world, UK, Canada, Saudi Arabia recently. It's a miracle cure that is real and worth billions. Current Mcap is ridiculously small at 4b.
The ambulance chaser lawsuits are pertaining to an event that happened in May of 2023 when the FDA turned down their HDE application for the pediatric SCD. [SeaStar Medical Provides Regulatory Update Related to its HDE Application for Pediatric Selective Cytopheretic Device](https://investors.seastarmedical.com/news/news-details/2023/SeaStar-Medical-Provides-Regulatory-Update-Related-to-its-HDE-Application-for-Pediatric-Selective-Cytopheretic-Device/default.aspx) The FDA indicated that the application is not approvable in its current form but outlined specific guidance as to how the application may be amended and resubmitted successfully-- The FDA later approved the resubmission. Please read the risk factors located in the company's 10-K, you will understand that there is no ground for litigation here. The lawsuits have no validity whatsoever. Ambulance chaser law firms that attack everyone hoping something sticks. Just look at their websites.
CRSP They just cured SCD and have more in the pipeline, future of medicine. https://www.bbc.co.uk/news/articles/c4gzldll44lo The stock is extremely undervalue right now. I'm all in.
Not to be a sarcastic ass once again. But this is Dot Com 2.0. If you are DCA into the market, it maybe time to start a position in either $RSP, $SCD, and/or $GLD if you haven't already. Market corrections teach you the need to diversify. Everyone looks like a fricking genius in a bull market. Those that diversify and stay in during bear markets win the day. It's easier to stay in the market when everything you own isn't blood Red every day, week, month, & year in market corrections. That's why hedges like Gold are needed in a port. Gold helped me stay in the market after dot com and 2008 GFC.
I think it has a decent shot as a looong hold, but not really expecting a big short term move without a catalyst. I took profits for now but I'm still watching it, maybe play the run up to adult approval and/or their first earnings call with SCD revenue.
Hear me out… ICU. Do your own DD, but if you have a fundamental knowledge of the human anatomy, you’ll see what a big deal their “SCD” is. If you don’t look at it in-depth, don’t cry later. Save this for 1 year.
You can read up on side effects of Casgevy vs the vector based treatment for SCD that was approved at the same time. I would say it speaks volumes.
Why do you think it's not priced in, and why would their SCD device be a major innovation? I'm not too deep into the medical field so any info is appreciated.
Crsp is a promising one considering they hold many patents on their new and emerging gene therapy, Crispr- Cas9. This technology is about 10 years old now but it has been incredibly impactful and revolutionary to the scientific community. Their new product, in collaboration with Vertex Pharmaceuticals 60/40, Casgevy, just got approved by the European Commission to treat sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). These are diseases with currently no cure until now (provided it shows good results in their limited release to 8000 patients) they plan to do the same with autoimmune diseases such as lupus which currently also has no cure. There are still results that need to be seen but it’s definitely going in the right direction and looks promising. As such with biotech, there is still a lot of risk in it still but with a current market cap of 7B, positive earnings, and alot of cash in hand to continue their studies, I can definitely say I like this stock! Will be holding for awhile and adding on dips. I am not a financial advisor!!
Any thoughts on the ICU sell-off? I don't think it's merely a sell the news event. IMO, a significant factor in why it fell so hard is the fact that it's a HDE approval rather than a full FDA approval. I think people did DD pertaining to SCD-PED upon receiving the news and saw that the market for this device is extremely small.
Yes. This is only the start for ICU I think. low $0.80s a good start for anyone new as well. Big accumulation here and I expect buyout ultimately. A lot to like about this company and most importantly their SCD device.
I'm in with 45,000 shares. Was tough that the de-SPAC transaction really happened at the worst time (Fall 2022) and just allowed for bleeding/shorting. On the bright side, their SCD-PED looks like it's on the verge of FDA approval; which means SeaStar will officially begin generating revenue. Seems like this would be the time to average down if you are in this from 20223 or early 2023.
Junk stock being pumped. Interesting. What I have read and researched is that $ICU SeaStar Medical's SCD is an innovative disruptive technology that is clinically showing incredible efficacy that is statistically significant in almost every way imaginable. In a high percentage of AKI cases to date, SCD has not only stopped inflammation, but it has also reversed kidney damage for patients with renal failure. It has been so effective, it has actually in some cases completely eliminated dialysis dependency. It is saving lives and drastically improving patient outcomes. It is also indication agnostic, so the potential and scope of the application is vast. It has also shown effective in helping the body bounce back to a stable level of vitals and strength, so they can then have life-saving organ transplants surgery or LVAD implants. So as convincing an argument as you make, I respectfully disagree based on the science, clinical date to date and scope of indications. My personal thesis is that this breakthrough discovery and resulting SCD device will change the landscape of patient care relative to patient's fighting inflammation and cytokine storms. It will be adopted by such a high percentage of hospitals, that it will universally be recognized as the new standard of care for patients fighting inflammation and cytokine storms
I hear you on this. Fair argument. I will say this, I have been surprised by some of their moves, but I have seen in time that it all lends itself to very strong execution in my opinion. So I am personally very bullish on the SeaStar leadership team. I think you will see a 2 months time that they have played this beautifully and set the company, the shareholders, and their SCD technology up for great success.
"SeaStar Medical expects to receive U.S. Food & Drug Administration (FDA) approval for its SCD Pediatric (SCD-PED) under a Humanitarian Device Exemption (HDE) for use in children weighing 10 kilograms or more with AKI and sepsis or a septic condition requiring continuous CKRT anytime within the next 30 to 45 days and to commence commercialization of the SCD-PED in Q1 2024." - December 28, 2023 Source: [https://investors.seastarmedical.com/news/news-details/2023/SeaStar-Medical-Updates-Subject-Enrollment-in-its-Pivotal-Trial-with-the-Selective-Cytopheretic-Device-in-Adults-with-Acute-Kidney-Injury/default.aspx](https://investors.seastarmedical.com/news/news-details/2023/seastar-medical-updates-subject-enrollment-in-its-pivotal-trial-with-the-selective-cytopheretic-device-in-adults-with-acute-kidney-injury/default.aspx)
Why does that seem... high? If SCD-ADULT receivs FDA approval next year (2025), they now have a 200,000 person market annually for their first indication. If treatment costs $5000 (I have no idea how much it costs but that sounds like a fair number), that's $1b revenue. And that is from a single indication. $1b annual revenue would put us at what marketcap? Idk. $1b marketcap puts us at like $20/share. Seems pretty low to me by the END of 2027. But... i dunno.
Guys, the stock has only dipped down to where it was LAST WEEK. It's been doing nothing but going up for a while, and at the first dip, people wanna bail? It went down for a reason. The SCD is still pending FDA approval, it's still going to be in a lot of hospitals. The company isn't tanking, the price is still up 44% compared to a month ago. Stocks are not always easy money, just stay calm guys, it will recover soon.
Not worried in the slightest. Shelf offering thats been in their financials for a year. Funding was necessary to expedite SCD-ADULT trials. After FDA approval, no need for reverse split or additional dilution. Clearer path ahead. Also smart by management to drop that AH as there is less volume/liquidity for people to panic. Smart investors understood what was happening and bought up those shares. That's why we are back to .77. I'll be buying more shares tomorrow.
$ICU wow looks promising bought in at .82 with 500 shares 📈 “Regardless of its source, uncontrolled hyperinflammation can lead to vital organ damage and even death. Our SCD therapy works to selectively target the most highly activated cells responsible for inflammation to bring activated cells into a reparative state. This can stop the potential damage of over-activated cells and potentially reverse the damage they cause.” What ya think of this one ? Input
This is an uneducated take. Bag holders implies unwarranted price movement to the upside, followed by early loaders selling their shares to new investors. You clearly don't understand the value of going from pre-revenue to revenue as a medtech company. You clearly don't understand the significance of FDA approval on share price or market cap or long term projections. You're view is severely short-sighted. SCD-PED approval, SCD-PED commercial launch, SCD Adult trial results, SCD Adult approval, SCD-Adult commercial launch all before Q2 2025. This doesn't include any of the other indications. You're lack of effort isn't even worth the downvote. Enjoy the sidelines.
You can if you want. It will likely move in the same direction. My problem with Nuwellis long term, is that the agreement is only for the SCD-PED... which means that they don't have the agreement for the adult version. This is the MUCH larger market. Also, if there is any sort of buyout/bigger company that swoops in.. ICU holds the patent. Nuwellis could get left in the dust. Unlikely, but possible.
Any shares bought now will payout huge on approval, and even more significantly if held through the SCD adult study, approval, and commercial launch.